IL-6 −572C>G and CARD8 304T>A Genetic Polymorphisms are Associated with the Absolute Neutrophil Count in Patients with Hematological Malignancies Under Chemotherapy: An Application of Multilevel Models to a Preliminary Pharmacogenetic Study

References

• Klastersky J, De Naurois J, Rolston K, et al. Management of febrile neutropaenia: ESMO clinical practice guidelines. Ann Oncol. 2016;27(suppl_5):v111–v118. doi:10.1093/annonc/mdw32527664247
   PubMed Web of Science ®Google Scholar
• Yılmaz Ş, Ören H, Demircioğlu F, I˙ Rken G. Assessment of febrile neutropenia episodes in children with acute leukemia treated with BFM protocols. Pediatr Hematol Oncol. 2008;25(3):195–204. doi:10.1080/0888001080193823118432502
   PubMed Web of Science ®Google Scholar
• Castagnola E, Fontana V, Caviglia I, et al. A prospective study on the epidemiology of febrile episodes during chemotherapy-induced neutropenia in children with cancer or after hemopoietic stem cell transplantation. Clin Infect Dis. 2007;45(10):1296–1304. doi:10.1086/52253317968824
   PubMed Web of Science ®Google Scholar
• Lehrnbecher T, Robinson P, Fisher B, et al. Guideline for the management of fever and neutropenia in children with cancer and hematopoietic stem-cell transplantation recipients: 2017 update. J Clin Oncol. 2017;35(18):2082–2094. doi:10.1200/JCO.2016.71.701728459614
   PubMed Web of Science ®Google Scholar
• Taplitz RA, Kennedy EB, Bow EJ, et al. Outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America clinical practice guideline update. J Clin Oncol. 2018;36(14):1443–1453. doi:10.1200/JCO.2017.77.621129461916
   PubMed Web of Science ®Google Scholar
• van der Most RG, Currie AJ, Robinson B, Lake RA. Decoding dangerous death: how cytotoxic chemotherapy invokes inflammation, immunity or nothing at all. Cell Death Differ. 2008;15(1):13. doi:10.1038/sj.cdd.440225518007666
   PubMed Web of Science ®Google Scholar
• Vyas D, Laput G, Vyas AK. Chemotherapy-enhanced inflammation may lead to the failure of therapy and metastasis. Onco Targets Ther. 2014;7:1015. doi:10.2147/OTT.S6011424959088
   PubMed Web of Science ®Google Scholar
• Rose-John S, Winthrop K, Calabrese L. The role of IL-6 in host defence against infections: immunobiology and clinical implications. Nat Rev Rheumatol. 2017;13(7):399. doi:10.1038/nrrheum.2017.8328615731
   PubMed Web of Science ®Google Scholar
• Wilkinson AN, Gartlan KH, Kelly G, et al. Granulocytes are unresponsive to IL-6 due to an absence of gp130. J Immunol. 2018;200(10):3547–3555. doi:10.4049/jimmunol.170119129626088
   PubMed Web of Science ®Google Scholar
• Chiba Y, Mizoguchi I, Hasegawa H, et al. Regulation of myelopoiesis by proinflammatory cytokines in infectious diseases. Cell Mol Life Sci. 2018;75(8):1363–1376. doi:10.1007/s00018-017-2724-529218601
   PubMed Web of Science ®Google Scholar
• Panayides A, Ioakeimidou A, Karamouzos V, et al. -572 G/C single nucleotide polymorphism of interleukin-6 and sepsis predisposition in chronic renal disease. Eur J Clin Microbiol Infect Dis. 2015;34(12):2439–2446. doi:10.1007/s10096-015-2500-026463449
   PubMed Web of Science ®Google Scholar
• Groslambert M, Py BF. Spotlight on the NLRP3 inflammasome pathway. J Inflamm Res. 2018;11:359. doi:10.2147/JIR.S14122030288079
   PubMed Web of Science ®Google Scholar
• Miller LS, Pietras EM, Uricchio LH, et al. Inflammasome-mediated production of IL-1β is required for neutrophil recruitment against Staphylococcus aureus in vivo. J Immunol. 2007;179(10):6933–6942. doi:10.4049/jimmunol.179.10.693317982084
   PubMed Web of Science ®Google Scholar
• Al-Gwaiz LA, Babay HH. The diagnostic value of absolute neutrophil count, band count and morphologic changes of neutrophils in predicting bacterial infections. Med Princ Pract. 2007;16(5):344–347. doi:10.1159/00010480617709921
   PubMed Web of Science ®Google Scholar
• Bangdiwala SI. The multilevel diagram. Int J Inj Contr Saf Promot. 2012;19(4):388–390. doi:10.1080/17457300.2012.73404023116170
   PubMed Web of Science ®Google Scholar
• Bates D, Mächler M, Bolker B, Walker S. Fitting linear mixed-effects models using lme4. arXiv Preprint arXiv. 2014.
   Google Scholar
• Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO. Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol. 2002;20(24):4713–4721. doi:10.1200/JCO.2002.02.14012488418
   PubMed Web of Science ®Google Scholar
• Akpek G, Knight RD, Wright DG. Use of oral mucosal neutrophil counts to detect the onset and resolution of profound neutropenia following high‐dose myelosuppressive chemotherapy. Am J Hematol. 2003;72(1):13–19. doi:10.1002/ajh.1025012508262
   PubMed Web of Science ®Google Scholar
• Sharma A, Singh K, Biswas A, et al. Impact of interleukin 6 promoter polymorphisms (− 174 G> C,− 572 G> C and− 597 G> A) on plasma IL-6 levels and their influence on the development of DVT: a study from India. Hematology. 2018;23(10):833–838. doi:10.1080/10245332.2018.148354629890913
   PubMed Web of Science ®Google Scholar
• Lok LS, Farahi N, Juss JK, et al. Effects of tocilizumab on neutrophil function and kinetics. Eur J Clin Invest. 2017;47(10):736–745. doi:10.1111/eci.1279928796316
   PubMed Web of Science ®Google Scholar
• Paramel G, Sirsjö A, Fransén K. Role of genetic alterations in the NLRP3 and CARD8 genes in health and disease. Mediators Inflamm. 2015;2015:1–10. doi:10.1155/2015/846782
   Web of Science ®Google Scholar
• Pathan N, Marusawa H, Krajewska M, et al. TUCAN, an antiapoptotic caspase-associated recruitment domain family protein overexpressed in cancer. J Biol Chem. 2001;276(34):32220–32229. doi:10.1074/jbc.M10043320011408476
   PubMed Web of Science ®Google Scholar
• Melhem M, Delor I, Pérez Ruixo JJ, et al. Pharmacokinetic–pharmacodynamic modelling of neutrophil response to G‐CSF in healthy subjects and patients with chemotherapy‐induced neutropenia. Br J Clin Pharmacol. 2018;84(5):911–925. doi:10.1111/bcp.1350429318653
   PubMed Web of Science ®Google Scholar
• Craig M, Humphries AR, Nekka F, Bélair J, Li J, Mackey MC. Neutrophil dynamics during concurrent chemotherapy and G-CSF administration: mathematical modelling guides dose optimisation to minimise neutropenia. J Theor Biol. 2015;385:77–89. doi:10.1016/j.jtbi.2015.08.01526343861
   PubMed Web of Science ®Google Scholar
• Ludwig H, Bokemeyer C, Aapro M, et al. Chemotherapy-induced neutropenia/febrile neutropenia prophylaxis with biosimilar filgrastim in solid tumors versus hematological malignancies: MONITOR-GCSF study. Future Oncol. 2019;15(8):897–907. doi:10.2217/fon-2018-081430827127
   PubMed Web of Science ®Google Scholar